 Percutaneous coronary intervention PCI is a common treatment for patients with severe ischemic heart disease. In the majority of cases, the potent anti-platelet agent eptifibatide is administered bolus followed by infusion for 18 hours. The principal reason to use eptifibatide for PCI is to prevent platelet aggregation and the associated ischemia and myocardial infarction MI. With improved laminar flow following stenting, prolonged infusion of eptifibatide may no longer be necessary. We hypothesize that after successful stenting with good angiographic results, patients can have eptifibatide discontinued immediately without a higher risk of adverse ischemic outcome, i.e. death, MI or unplanned target vessel revascularization TVR by 30 days. MI is defined as creatine kinase-MB CK-MB concentrations elevated to more than three times the upper limit of normal or new pathologic Q wave as seen on electrocardiograms ECG. In order to prove this hypothesis, we estimate a sample size of 2,100 patients. 